Cargando empresa
Just reported
From Sarepta Therapeutics's results release of 5 de noviembre de 2026; its quarterly report has since been filed.
Actual
381,4M US$
-4,5 % y/y
-5,0 % q/q
Guided
—
No guide given
Actual
-0,27 US$
Guided
—
No guide given
Actual
-9M US$
Guided
—
No guide given
Operating income, adjusted: 22,9M US$
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Sarepta Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B US$A+
EXELExelixis, Inc.16,8B US$A+
JAZZJazz Pharmaceuticals plc15,5B US$A
TECHBIO-Techne Corp11,4B US$A+
HALOHalozyme Therapeutics, Inc.11,4B US$A+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct 2026CAGraded C, now AEstados financieros completos →
Construido a partir de los propios informes de Sarepta Therapeutics, Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
Grade C
La franja bajo el precio muestra la calificación en cada fecha, calculada solo con los informes ya públicos en ese momento.
Mostrando 2 de 40 trimestres del historial de calificaciones de Sarepta Therapeutics, Inc.. Los otros 38 llegan hasta febrero de 2017.
